Uncategorized
No greater risk for death seen with anti-VEGF vs. ablation for ROP
NASHVILLE, Tenn. — There was no statistically significant difference in mortality in premature infants with retinopathy of prematurity treated with anti-VEGF or with retinal ablative therapy, according to a poster presented at the American Association for Pediatric Ophthalmology and Strabismus meeting. “We undertook this study to address the possibility of increased death rate in premature infants that have been treated with anti-VEGF for ROP,” Iason S. Mantagos, MD, and colleagues from Boston Children’s Hospital wrote.